Acelyrin (NASDAQ:SLRN - Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.
Acelyrin (NASDAQ:SLRN - Get Free Report) last posted its earnings results on Wednesday, March 19th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.07. On average, analysts expect Acelyrin to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Acelyrin Price Performance
NASDAQ SLRN traded down $0.02 on Friday, hitting $2.75. The company had a trading volume of 1,392,082 shares, compared to its average volume of 1,209,203. The company has a market capitalization of $275.90 million, a PE ratio of -1.12 and a beta of 1.25. The company's fifty day moving average price is $2.29 and its 200-day moving average price is $3.81. Acelyrin has a 12-month low of $1.85 and a 12-month high of $7.30.
Wall Street Analysts Forecast Growth
SLRN has been the subject of a number of research reports. Wells Fargo & Company dropped their target price on shares of Acelyrin from $15.00 to $13.00 and set an "overweight" rating for the company in a report on Wednesday, December 11th. HC Wainwright dropped their price objective on shares of Acelyrin from $8.00 to $6.00 and set a "neutral" rating for the company in a report on Tuesday, January 7th. Finally, Citigroup decreased their target price on shares of Acelyrin from $6.00 to $3.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, Acelyrin has a consensus rating of "Hold" and a consensus price target of $9.60.
Check Out Our Latest Stock Analysis on Acelyrin
Insider Buying and Selling at Acelyrin
In other news, CEO Mina Kim sold 17,986 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the transaction, the chief executive officer now directly owns 671,753 shares in the company, valued at approximately $1,840,603.22. This trade represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 13.60% of the stock is currently owned by insiders.
Acelyrin Company Profile
(
Get Free Report)
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Further Reading
Before you consider Acelyrin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acelyrin wasn't on the list.
While Acelyrin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
